Chemoattractant mechanism of Th1 cells in class III and IV lupus nephritis

References

• Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15: 2694–2704
   PubMed Web of Science ®Google Scholar
• Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, Hashimoto H. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)—relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999; 116: 169–173
   PubMed Web of Science ®Google Scholar
• Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877–885
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 1989; 72: 779–833
   PubMedGoogle Scholar
• McLaughlin J, Gladman DD, Urowitz MB, Bombardier C, Farewell VT, Cole E. Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 1991; 34: 1268–1273
   Google Scholar
• McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994; 37: 559–567
   Google Scholar
• Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994; 3: 107–112
   PubMed Web of Science ®Google Scholar
• Kashgarian M. Lupus nephritis: patology, pathogenesis, clinical correlations, and prognosis. Duboi's lupus erythematosus5th ed., DJ Wallace, BH Hahn, 1997; 1037–1051
   Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–146
   PubMedGoogle Scholar
• Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097–2106
   PubMed Web of Science ®Google Scholar
• Rovin BH, Rumancik M, Tan L, Dickerson J. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994; 71: 536–542
   PubMed Web of Science ®Google Scholar
• Tipping PGKA, Holdworth SR. The Formation of Glomerular Crescents. Lippincott Williams & Wilkins, Phildelphia, PA 2001
   Google Scholar
• Allavena P, Bianchi G, Zhou D, van Damme J, Jilek P, Sozzani S, Mantovani A. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994; 24: 3233–3236
   PubMed Web of Science ®Google Scholar
• Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994; 91: 3652–3656
   PubMed Web of Science ®Google Scholar
• Valente AJ, Graves DT, Vialle-Valentin CE, Delgado R, Schwartz CJ. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 1988; 27: 4162–4168
   PubMed Web of Science ®Google Scholar
• Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108–115
   PubMed Web of Science ®Google Scholar
• Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 1993; 69: 83–91
   PubMedGoogle Scholar
• Wada T, Furuichi K, Segawa-Takaeda C, Shimizu M, Sakai N, Takeda SI, Takasawa K, Kida H, Kobayashi KI, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999; 56: 995–1003
   PubMed Web of Science ®Google Scholar
• Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49: 761–767
   PubMed Web of Science ®Google Scholar
• Rovin BH, Phan LT. Chemotactic factors and renal inflammation. Am J Kidney Dis 1998; 31: 1065–1084
   PubMed Web of Science ®Google Scholar
• Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997; 8: 720–729
   PubMed Web of Science ®Google Scholar
• Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas[lpr] mice. J Exp Med 1999; 190: 1813–1824
   PubMed Web of Science ®Google Scholar
• Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997; 186: 131–137
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Morimoto S, Kaneko H, Nozawa K, Tokano Y, Takasaki Y, Hashimoto H. Decreased IL-4 producing CD4+T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression. Autoimmunity 2002; 35: 381–387
   PubMed Web of Science ®Google Scholar
• Kaneko H, Ogasawara H, Naito T, Akimoto H, Lee S, Hishikawa T, Sekigawa I, Tokano Y, Takasaki Y, Hirose SI, Hashimoto H. Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol 1999; 26: 568–573
   PubMed Web of Science ®Google Scholar
• Morimoto S, Tokano Y, Kaneko H, Nozawa K, Amano H, Hashimoto H. The increased interleukin-13 in patients with systemic lupus erythematosus: relations to other Th1- Th2-related cytokines and clinical findings. Autoimmunity 2001; 34: 19–25
   PubMed Web of Science ®Google Scholar
• Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, Capon DJ, Tedder TF. Lymphocyte homing and leukocyte rolling and migration are impaired in l-selectin-deficient mice. Immunity 1994; 1: 247–260
   PubMed Web of Science ®Google Scholar
• Csiszar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E. Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000; 122: 464–470
   PubMed Web of Science ®Google Scholar
• Esfandiari E, McInnes IB, Lindop G, Huang FP, Field M, Komai-Koma M, Wei X, Liew FY. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 2001; 167: 5338–5347
   PubMed Web of Science ®Google Scholar
• Tang ML, Steeber DA, Zhang XQ, Tedder TF. Intrinsic differences in l-selectin expression levels affect T and B lymphocyte subset-specific recirculation pathways. J Immunol 1998; 160: 5113–5121
   PubMed Web of Science ®Google Scholar
• Gauguet JM, Rosen SD, Marth JD, von Andrian UH. Core 2 branching beta1,6-N-acetylglucosaminyltransferase and high endothelial cell N-acetylglucosamine-6-sulfotransferase exert differential control over B- and T-lymphocyte homing to peripheral lymph nodes. Blood 2004; 104: 4104–4112
   PubMedGoogle Scholar
• Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103: 773–778
   PubMed Web of Science ®Google Scholar
• Lee SK, Kim BS, Yang WS, Kim SB, Park SK, Park JS. High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney Int 2001; 60: 55–64
   Google Scholar
• Romagnani P, Lazzeri E, Lasagni L, Mavilia C, Beltrame C, Francalanci M, Rotondi M, Annunziato F, Maurenzig L, Cosmi L, Galli G, Salvadori M, Maggi E, Serio M. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J Am Soc Nephrol 2002; 13: 53–64
   Google Scholar
• Papadakis KA, Zhu D, Prehn JL, Landers C, Avanesyan A, Lafkas G, Targan SR. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+T lymphocytes. J Immunol 2005; 174: 4985–4990
   PubMed Web of Science ®Google Scholar
• Tokano Y, Suzuki J, Amano H, Nozawa K, Morimoto S, Hashimoto H. Increased levels of interleukin-18 in patients with systemic lupus erythematosus: comment on the article by Shibatomi et al. Arthritis Rheum 2002; 46: 1410–1411, author reply 1411–1412
   Google Scholar